Introduction The Lobular Breast Cancer Alliance (LBCA) was founded in 2017 by patient advocates attending the First International Invasive Lobular Breast Cancer Symposium sponsored by the University of Pittsburgh. The conference underscored that invasive lobular breast cancer (ILC) is an understudied unique subtype of breast cancer requiring refinements in treatments. ILC is the sixth most frequently diagnosed cancer of women and the second most common histological subtype of breast cancer with more than 39,000 patients diagnosed a year in the U.S. LBCA’s goals are to advance research and educate about ILC. Challenges An early goal of LBCA was to address the absence of a central source of quality information about lobular breast cancer. A website, lobularbreastcancer.org, launched December, 2017 with over 98,000 hits to-date. It is maintained by patient-advocate volunteers with content reviewed by LBCA’s Scientific Advisory Board. Methods A survey of users was conducted from May 1 to June 3, 2019 to determine value of the website to users and identify potential ways to improve it. Specific goals were: Understand who was visiting the site, identify the information sought, obtain feedback on the usefulness of content, and seek input on content and navigation. Results The online survey was taken by 950 participants. Current or former patients treated for lobular breast cancer comprised 94.7% of respondents. 75.8% were from U.S. Health professionals/researchers represented 3.04% of responders. Patients ranged in age from under 35 to over 75 years; 71.5% were 46-65 years. Most (66.5%) had Stage 1-2 disease at time of diagnosis; 7% reported de novo metastatic disease. An additional 9% reported a metastatic recurrence. LBCA (43.8%), other cancer organizations (43.2%),and Internet searches (38.3%) were the most frequently used sources for information about lobular breast cancer; doctor/health care provider ranked fourth (35.3%). The survey confirmed that LBCA goals for the website were aligned with the reason responders visited - i.e., general information (33%), research/clinical trials (21.9%) and treatment information (17.8%). Most consulted the site 2-4 times (46%), 11% visited more than 10 times. Nearly all responders (83.7%) found the information they were seeking, and (45.4%) agreed that the LBCA website provided information they could not find elsewhere. There were 249 participants who responded to an open ended question with 273 recommendations for the site. The largest category of requests (17%) was for more frequent updates of research and treatment guidelines; requests for a list of providers with expertise in treating ILC patients and for LBCA to provide additional education about ILC to MDs/clinicians ranked second and third (11%). Conclusions LBCA is driving increased awareness of lobular breast cancer by sponsoring a website devoted to providing research-based information about lobular breast cancer. There were a number of actionable suggestions regarding organization and navigation of the LBCA website. Results confirmed that the LBCA goals for the website are aligned with the reason responders visited. Primarily, users searched for general information about ILC (33%), research/clinical trials (21.9%) and treatment information (17.8%). The need for a central online source for information about lobular breast cancer was confirmed by findings that the most frequently used sources of information about lobular were the LBCA, other cancer organizations and Internet searches. Doctors/health care providers ranked fourth as a source of information about lobular disease. Many responders wanted the website to list ILC treatment specialists, address the gap in provider expertise about ILC detection and treatment, and report research and treatment guidelines specifically for ILC. Citation Format: Lori Petitti, Janice Axelrod, Margaret Campbell-Kotler, Julia Levine, Flora Migyanka, Elizabeth Viggiano, Steffi Oesterreich, Leigh Pate. Survey of Lobular Breast Cancer Alliance website users confirms value and identifies unmet information needs [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-16-02.
Introduction Thirty patient advocates attended the First International Invasive Lobular Breast Cancer Symposium in 2016 at the University of Pittsburgh Cancer Center. The conference underscored that invasive lobular breast cancer (ILC) and other lobular pathologies are understudied. Specifically: ILC is the sixth most prevalent cancer of women and the second most frequently diagnosed histological subtype of breast cancer impacting up to 34,000 patients a year in the US. ILC is a molecularly distinct breast cancer with unique subtypes and variants with differences in presentation and behavior, including physical findings of thickening and a tendency to metastasize to unique locations. While ILC is frequently associated with a good initial prognosis, recent analysis suggests that long-term outcomes of ILC may be worse than those stage-matched to ductal breast cancer. Current imaging tools are less reliable for early detection of lobular disease and detection of distant recurrence. Standard of care chemotherapy and endocrine therapies may have different effectiveness applied to ILC and IDC. Challenges Growing interest in ILC research requires improved methods to identify, communicate with and link patients with ILC to clinical trials and research. Advocates with advanced science training are needed as partners for research proposals and grant reviews. Lobular breast cancer is under-represented in key meetings and literature. Encouraging opportunities to share ILC research as agenda topics and fostering collaborations between researchers, clinicians and advocates can accelerate progress and refine clinical practices for screening, treatment and follow-up. Patients living with ILC lack a central on-line source of lobular breast cancer information and resources. This information gap is a barrier to help patients recognize signs of lobular breast cancer's unique presentation and metastatic behaviors. Results The Lobular Breast Cancer Alliance (LBCA) was formed by patient advocates who attended the First International ILC Symposium in response to advocate-identified opportunities to advance research, refine treatments and enhance patient education. LBCA's mission is to bridge patients, clinicians and researchers to increase our knowledge of lobular breast disease and promote research that leads to advancements in prevention, diagnosis, treatment and patient follow-up care. Conclusions LBCA is driving an increased awareness of lobular breast cancer with specific goals: Build a clinically accurate, patient centered website devoted to lobular breast cancer at www.LobularBreastCancer.org. Elevate lobular research and foster opportunities for researcher, advocate and clinician collaborations at prominent conferences and meetings. Identify barriers to conduct research on ILC and metastasis and link patients and advocates to ILC tumor research and clinical trials. Initiate peer-to-peer clinician outreach strategy through targeted literature, meetings and education services to share information on ILC presentation, metastatic patterns and screening and treatment challenges of patients with ILC. Build partnerships with existing breast cancer organizations to integrate ILC into existing information resources and work on common goals. Citation Format: Petitti L, Axelrod J, Campbell-Kotler M, Frank E, Jaremek J, Levine J, McWilliams M, Migyanka F, Ryan N, Viggiano E, Metzger-Filho O, Oesterreich S, Pate L. Lobular breast cancer alliance - Advocates advancing research, screening, treatment and follow-up care for lobular breast disease [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-17-01.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.